PLUS THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-3.2% -$45K
$1M
Cost of Revenue
—
Gross Profit
—
R&D↑+34.5% +$755K
$3M
D&A↓-58.3% -$203K
$145K
Operating Income↓-18.0% -$683K
$-4M
EBITDA↓-58.3% -$203K
$145K
Interest Expense↓-100.0% -$57K
$0
Interest Income↓-46.3% -$25K
$29K
Net Income↓-53.9% -$2M
$-4M
Gross Margin
—
Operating Margin↓-59.9pts
-320.8%
Net Margin↓-119.2pts
-316.6%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↓-42.0pts
-21.0%
ETR State + Local (pp)↓-0.5pts
-0.2%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost↑+1147.4% +$218K
$237K
Revenue YoY Variation↑+47.9pts
-3.2%
Income YoY Variation↓-1.1pts
-18.0%
Revenue QoQ Variation↑+0.9pts
-2.1%
Income QoQ Variation↓-188.7pts
-191.4%